Bivalirudin TFA

Product Details
Formula	C98H138N24O33.C2HF3O2
Molecular Weight	2294.34
Appearance	Solid
Purity	99.89%
Sequence	{d-Phe}-Pro-Arg-Pro-Gly-Gly-Gly-Gly-Asn-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu
Sequence Shortening	{d-Phe}-PRPGGGGNGDFEEIPEEYL

Storage & Handling
Shipping	Room temperature.
Storage	Sealed storage, away from moisture and light *In solvent : -80 °C, 6 months; -20 °C, 1 month (sealed storage, away from moisture and light)
Storage Powder	-80 °C/2 years, -20 °C/1 year

Bivalirudin TFA is a synthetic 20 residue peptide which reversibly inhibits thrombin. IC50 Value: Target: thrombin in vitro: Eptifibatide (8 mg/mL) added together with a low (70 ng/mL) concentration of bivalirudin (a direct thrombin inhibitor) effectively (approximately 90%) reduced platelet aggregation induced by thrombin (0.2 U/mL) . In thrombin generation assay (TGA), bivalirudin had no effect on these parameters up to 10 μmol/l . Bivalirudin-facilitated binding of MPO to BAEC resulted also in functional changes in terms of increased NO consumption as well as enhanced MPO-mediated redox modifications . in vivo: The use of bivalirudinprevented further increase in antiheparin/PF4 antibody IgG levels in rats . Three animals in the 500-mg/kg/24 h group, and 7 animals in the 2000-mg/kg/24 h group in the toxicokinetic assessment phase of the study were found dead or euthanized in extremis (following blood sampling). Plasma concentrations of bivalirudin appeared to be linear and dose independent . Clinical trial: Antithrombotic Effects of Ticagrelor Versus Clopidogrel . Phase 4

! For research use only. Not intended for any clinical use.